👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

BMO maintains $90 target on Legend Biotech shares amid approval optimism

EditorEmilio Ghigini
Published 03/14/2024, 07:58 AM
© Reuters.

© Reuters.

LEGN
-0.88%

On Thursday, BMO Capital Markets sustained its positive outlook on Legend Biotech Corp (NASDAQ:LEGN), maintaining an Outperform rating and a $90.00 price target for the company's shares. The firm's stance is bolstered by briefing documents indicating a favorable overall survival benefit for Legend Biotech's Carvykti, which could lead to its approval.

In a recent follow-up study, Carvykti showed a 77% overall survival rate at 29 months, compared to 64% in the standard of care, reflecting a hazard ratio of 0.57. This suggests a significant overall survival benefit. Despite the FDA's concerns about a higher death rate in the Carvykti arm during the initial ten months, BMO Capital does not view this as a significant obstacle to approval. The deaths were mostly unrelated to Carvykti, and the long-term benefits in terms of overall survival and progression-free survival are considered substantial.

The firm anticipates a favorable vote from the Oncologic Drugs Advisory Committee (ODAC) on March 15, 2024, and ultimately expects approval of Carvykti by the FDA on April 5, 2024. The analyst's comments reflect confidence in the drug's profile and the regulatory process, suggesting a strong potential for market approval.

Legend Biotech's Carvykti is under scrutiny for its efficacy and safety profile, with the FDA's review process being a critical phase for the company. BMO Capital's analysis and expectations are based on the available data and the upcoming ODAC review, pointing to a promising future for the treatment if approved.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

LEGN: A Bull or Bear Market Play?

Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if LEGN is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Unlock ProPicks AI now

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.